Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT

Diabetes

Volumn 60, Issue 5, 2011, Pages 1552-1560

  Kahn, Steven E ^a   Lachin, John M ^b   Zinman, Bernard ^c   Haffner, Steven M ^d   Aftring, R Paul ^e   Paul, Gitanjali ^e   Kravitz, Barbara G ^e   Herman, William H ^f   Viberti, Giancarlo ^g   Holman, Rury R ^h   Jones, Nigel ^e   O'Neill, Colleen ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d GlaxoSmithKline ^*

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 79959484802     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1392     Document Type: Article

References (21)

1. UK Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258
2. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-372 (Pubitemid 34256388)
3. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737-1743 (Pubitemid 41071079)
4. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 (Pubitemid 44903747)
5. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994;11:286-292 (Pubitemid 24144145)
6. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495 (Pubitemid 38680001)
7. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, Iowa, Iowa State University Press, 1980
8. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied Linear Statistical Models. Chicago, Irwin, 1996
9. Wu MC, Bailey KR. Estimation and comparison of changes in the presence of informative right censoring: conditional linear model. Biometrics 1989;45:939-955 (Pubitemid 19249332)
10. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979;28:1086-1096 (Pubitemid 10191950)
11. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and b-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-1672 (Pubitemid 23318125)
12. Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009;32:335-341
13. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3-19 (Pubitemid 36237741)
14. Kitabchi AE, Temprosa M, Knowler WC, et al.; Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005;54:2404-2414
15. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794 (Pubitemid 29536364)
16. Vandewalle B, Moerman E, Lefebvre B, et al. PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun 2008;366:1096-1101
17. Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002;51(Suppl. 1):S134-S137 (Pubitemid 34761508)
18. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-630 (Pubitemid 20169143)
19. Belsley DA, Kuh E, Welsch RE. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. New York, Wiley, 1980
20. Faulenbach MV, Lorenzo C, Utzschneider KM, et al. Prevalence of negative insulinogenic index by glucose tolerance in three different cohorts. Diabetes 2008;57(Suppl. 1):A669
21. Metz SA, Halter JB, Robertson RP. Paradoxical inhibition of insulin secretion by glucose in human diabetes mellitus. J Clin Endocrinol Metab 1979;48:827-835 (Pubitemid 9172121)